ReviewFrontiers in pediatrics2014
New experimental treatments for core social domain in autism spectrum disorders.
Review in Frontiers in pediatrics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- The Insulin-like Growth Factor Family as a Potential Peripheral Biomarker in Psychiatric Disorders: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- Phosphoproteomic profiling reveals reversal of dysregulated kinase signaling by nitric oxide inhibition in the Shank3 mouse model of autism.Scientific reports · 2026Article
- Lateral Habenula 5-HT₂A Receptors Mediate Social Deficits in a Valproic Acid-Induced Rodent Model of Autism Spectrum Disorder.Molecular neurobiology · 2026Article
- Article
- The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid.Molecular medicine reports · 2022Article
- Novel probiotic treatment of autism spectrum disorder associated social behavioral symptoms in two rodent models.Scientific reports · 2022Article
- Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Osterreichischer Nervenarzte und Psychiater · 2021Review
- The Autism Impact Measure (AIM): Examination of Sensitivity to Change.Autism research : official journal of the International Society for Autism Research · 2020Article
- Emerging connections between cerebellar development, behaviour and complex brain disorders.Nature reviews. Neuroscience · 2019Review
- Insulin-Like Growth Factors in the Pathogenesis of Neurological Diseases in Children.International journal of molecular sciences · 2017Review
- Maturation, Refinement, and Serotonergic Modulation of Cerebellar Cortical Circuits in Normal Development and in Murine Models of Autism.Neural plasticity · 2017Review
- Hypothesis on supine sleep, sudden infant death syndrome reduction and association with increasing autism incidence.World journal of clinical pediatrics · 2016Article
- The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.Current behavioral neuroscience reports · 2016Article
- NMDA receptor activation regulates sociability by its effect on mTOR signaling activity.Progress in neuro-psychopharmacology & biological psychiatry · 2015Review
- Dysfunction of social cognition and behavior.Continuum (Minneapolis, Minn.) · 2015Review
- New treatment perspectives in autism spectrum disorders.Frontiers in pediatrics · 2015Article
- Promoting social plasticity in developmental disorders with non-invasive brain stimulation techniques.Frontiers in neuroscience · 2015Review
- Recent advances in understanding synaptic abnormalities in Rett syndrome.F1000Research · 2015Review
- Behavioral impairments in animal models for zinc deficiency.Frontiers in behavioral neuroscience · 2014Review
- Structural plasticity: mechanisms and contribution to developmental psychiatric disorders.Frontiers in neuroanatomy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current therapeutics in autism spectrum disorders (ASD) only treat the associated symptoms, without addressing core social dysfunctions. A paradigm shift in research of the pathogenesis of ASD, its synaptic abnormalities and altered signaling in multiple dynamic systems, have led to new experimental treatments for treating the core social abnormalities of ASD. NMDA antagonists, especially memantine, have been introduced in clinical trials addressing glutamatergic transmission in children and adolescents with ASD. GABAergic signaling has been targeted in trials using the GABAB receptor agonist arbaclofen for ASD patients with promising results. Oxytocin has been recognized as implicated in social development and affiliative behaviors. Preliminary findings from clinical trials using oxytocin in children with ASD show encouraging improvements in social cognition, but larger studies are needed. In two of the single gene disorders associated with ASD, Insulin Growth Factor (IGF-1) is a new treatment that has been tested in Rett syndrome and Phelan-McDermid syndrome (Chromosome 22 deletion syndrome). IGF-1 has been demonstrated to reverse the reduction in the number of excitatory synapses and the density of neurons that characterize these conditions in animal studies and it is being introduced as an experimental treatment. As a novel approach to verify treatment efficacy, neural processing modifications were recently evaluated by fMRI after a pivotal response training intervention. Another study of neural changes in response to treatment examined variations in EEG signaling in patients after an Early Start Denver Model (ESDM) intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.